18 F-Labeled PET Tracers Specific for Adenosine A 2A Receptor: Design, Synthesis, and Biological Evaluation
Tingyu Yang,Wei Zheng,Xuebo Cheng,Hualong Chen,Zeng Jiang,Ziyue Yu,Lu Zhang,Yi Xie,Lianjie Du,Xuan Ge,Jiahuai Zhang,Leilei Yuan,Yajing Liu,Zehui Wu
DOI: https://doi.org/10.1021/acschemneuro.4c00066
2024-03-08
ACS Chemical Neuroscience
Abstract:By modifying the structures of targeted A<sub>2A</sub>R antagonists and tracers, novel compounds <b>3</b>, <b>7a</b>, <b>9</b>, <b>12c</b>, and BIBD-399 were designed and synthesized. In vitro inhibition experiments demonstrated that <b>3</b>, <b>12c</b>, and BIBD-399 have high affinity for A<sub>2A</sub>R. <b>[</b><sup><b>18</b></sup><b>F]3</b> and [<sup>18</sup>F]BIBD-399 were successfully synthesized. In terms of biological distribution, the brain uptake of [<sup>18</sup>F]MNI-444 exhibits greater than that of <b>[</b><sup><b>18</b></sup><b>F]3</b> and [<sup>18</sup>F]BIBD-399. PET imaging shows that <b>[</b><sup><b>18</b></sup><b>F]3</b> is off-target in the brain, while [<sup>18</sup>F]BIBD-399 and [<sup>18</sup>F]MNI-444 can be specifically imaged in regions with high A<sub>2A</sub>R expression. Differently, [<sup>18</sup>F]BIBD-399 could quickly reach equilibrium in the targeted region within 10 min after administration, while [<sup>18</sup>F]MNI-444 shows a slowly increasing trend within 2 h of administration. [<sup>18</sup>F]BIBD-399 is mainly metabolized by the liver and kidney, and there is no obvious defluorination in vivo. Additional in vitro autoradiography showed that the striatal signals of [<sup>18</sup>F]BIBD-399 and [<sup>18</sup>F]MNI-444 were inhibited by the A<sub>2A</sub>R antagonist SCH442416 but not by the A<sub>1</sub>R antagonist DPCPX, demonstrating the high A<sub>2A</sub>R binding specificity of [<sup>18</sup>F]BIBD-399. Molecular docking further confirms the high affinity of MNI-444 and BIBD-399 for A<sub>2A</sub>R. Further tMCAo imaging showed that [<sup>18</sup>F]BIBD-399 can sensitively distinguish between infarcted and noninfarcted sides, a capability not observed with [<sup>18</sup>F]MNI-444. Given its pharmacokinetic properties and the ability to identify lesion regions, [<sup>18</sup>F]BIBD-399 has potential advantages in monitoring A<sub>2A</sub>R changes, meriting further clinical investigation.
biochemistry & molecular biology,chemistry, medicinal,neurosciences